On the other hand, targeted treatments for mutant KRAS-driven lung adenocarcinoma and lung squamous cell carcinoma have not been developed other than chemotherapy that target both cancer cells and normal proliferating cells [7]–[9]. Here, KRAS is linked to lung adenocarcinoma.